Lethal undiagnosed very long-chain Acyl-CoA dehydrogenase deficiency with mild C14-acylcarnitine abnormalities on newborn screening

JIMD Reports

Volumn 6, Issue , 2012, Pages 113-115

  Spiekerkoetter, U ^a   Mueller, M ^a   Sturm, M ^a   Hofmann, M ^b   Schneider, D T ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Municipal Hospital Dortmund   (Germany)

Author keywords

Acylcarnitine profile; False positive case; Fatty acid oxidation disorder; Healthy newborn; Newborn screening

Indexed keywords

EID: 84924627532     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2012_129     Document Type: Chapter

References (11)

1. Arnold GL, Van Hove J, Freedenberg D et al (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96(3): 85–90
2. Boneh A, Andresen BS, Gregersen N et al (2006) VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. Mol Genet Metab 88(2):166–170
3. Ficicioglu C, Coughlin CR II, Bennett MJ et al (2010) Very long-chain acyl-CoA dehydrogenase deficiency in a patient with normal newborn screening by tandem mass spectrometry. J Pediatr 156(3):492–494
4. German AWMF Guidelines (2011) German AWMF guidelines for the confirmation diagnosis of metabolic diseases identified by newborn screening (guideline no 027/021). http://www.awmf.org. Accessed 11 July 2011
5. Liebig M, Schymik I, Mueller M et al (2006) Neonatal screening for very long-chain acyl-coA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels. Pediatrics 118(3):1065–1069
6. McGoey RR, Marble M (2011) Positive newborn screen in a normal infant of a mother with asymptomatic very long-chain acyl-CoA dehydrogenase deficiency. J Pediatr 158(6):1031–1032
7. McHugh DM, Cameron CA, Abdenur JE et al (2011) Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 13(3):230–254
8. Schymik I, Liebig M, Mueller M et al (2006) Pitfalls of neonatal screening for very-long-chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. J Pediatr 149 (1):128–130
9. Spiekerkoetter U, Huener G, Baykal T et al (2003) Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2. J Inherit Metab Dis 26(6):613–615
10. Spiekerkoetter U, Haussmann U, Mueller M et al (2010) Tandem mass spectrometry screening for very long-chain acyl-CoA dehydrogenase deficiency: the value of second-tier enzyme testing. J Pediatr 157(4):668–673
11. Wilcken B (2010) Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 33(5):501–506